SCHEDULE C
           DEVELOPMENT PROGRAM FOR NEUTRACEUTICAL AND COSMETIC AGENTS.

MAJOR  ITEMS
------------

SCALE-UP

     Bulk  isolation  and  purification  for  "batch"  preparations
     Time  2  months  (  2  weeks)

     a)  Along  the  way to full scale production pilot batches will be QA'd and
     combined  for  immediate  use  in  all  tests

     b)  Target  is  for  250  g  batch  sizes

ARTHRITIS  TRIALS

Time  6  months

This  includes:  1)  Ethics  Committee  approval  (application in by 29/1/99)
                 2)  Re-establishing  model  (active  and  passive)
                 3)  Delivery  and  dose-finding  studies  including
                         i)  Gavage
                        ii)  Drinking  water
                       iii)  Food
                        iv)  confirmation  by  mini-osmotic  pump  delivery

SKIN  TRIALS

     Time  6  -  8  months

     This includes:  1)  Formulation  preparations  (negotiations now going)
                     2)  Evaluate  dermal  delivery  formulations
                     3)  Establishing  a  model  for  quick delivery assessment
                     4)  Establish  a  wrinkle  model  and  test  materials

EXPECTED  TIMING
0-3  MONTHS

     PREPARATION  OF  BATCH  MATERIAL  FOR  ALL  SUBSEQUENT  TESTING.

     A large scale  preparation of material has been produced and purified using
     a gel filtration  procedure.  A quantity of approximately 50 grams has been
     purified but the gel filtration procedure is still inefficient and 50 grams
     is still not sufficient for the oral  availability  studies to be commenced
     (and completed).  A new and hopefully more efficient gel filtration  column
     is currently being installed in the laboratory for this purpose.


<PAGE>
     PRODUCE  FORMULATIONS  FOR  SKIN  TESTING

     Several skin  formulations  have been assessed in the rat model and to date
     none of these formulations have had an effect equivalent to the intradermal
     injection of material.  The skin formulations  tested to date have included
     ethanol,  DMSO and oleic acid. A  consultant  specialist  skin  formulation
     company  has  been  approached  to  provide  alternative  formulations  for
     testing.

     COMMENCE  TRIALS  IN  ANIMAL  MODELS  OF  RHEUMATOID  ARTHRITIS

     An animal model of rheumatoid  arthritis has been  established in rats. The
     model is called the adjuvant  arthritis model and is the result of adjuvant
     treatment of rats which causes joint swelling and inflammation within three
     weeks. Lymphocytes from adjuvant treated rats are transferred to naive rats
     and these rats develop  joint signs  within two weeks.  The severity of the
     arthritis is assessed by measuring  the thickness of the ankle joints daily
     and by histological  examination of the joints after two weeks.  Using this
     model  it  has  been  found  that  the  Praxis  agents   consistently   and
     significantly  reduce the severity of the  arthritis.  Several  agents have
     been tested and shown to work (see May, 2000 research report) in the model.
     The agents were administered by infusion pump into the subcutaneous  tissue
     over a two week period. Now that the model is established and we have shown
     the  efficacy of the agents  under  development  it is awaiting  sufficient
     material to test the oral  effectiveness  which  requires  the agents to be
     administered  in the drinking  water.  It is hoped that  sufficient will be
     available start this in 3 weeks time.

3-6  MONTHS

     TEST  SKIN  FORMULATIONS  FOR  PENETRATION  AND  EFFECT

     As noted above several skin  formulations have been produced and tested for
     their  effectiveness  in remodeling the skin of rats. No formulations  have
     been  as  effective  as  an  intradermal  injection.  Penetration  is to be
     assessed in the future using  fluorescently  labeled  material which can be
     assessed for penetration using standard immunohistology procedures.

     COMPLETE  RHEUMATOID  ARTHRITIS  ANIMAL  STUDIES

     As noted these  studies  cannot  commence  until  sufficient  material  has
     finally been purified (100 grams).

6-9  MONTHS

     BEGIN  SKIN  TOXICITY  STUDIES

     Preliminary  skin  toxicity  studies have been done in rats.  These studies
     were of two weeks  duration.  No adverse  effects  were  observed by visual
     inspection or by histological examination.  More extended studies are to be
     performed in the next three months including UV exposure effects.

     FILE  SKIN  COSMETIC  PATENT  (MATERIAL  AND  FORMULATION  COVERAGE)

     A provisional  patent has been drafted but not yet filed. The patent covers
     the  agents   structure   and  the  use  for   management  of  wrinkles  by
     administration  topically and by injection.  Finalization of the patent and
     filing is expected to be completed in 2-3 weeks.

9-12 MONTHS

     COMPLETE  SKIN  TOXICITY  STUDIES

     See  comments  above

     COMMENCE  ANIMAL  WRINKLE  MODEL  STUDIES

     A specialized UV  irradiation  system is currently  being  installed in the
     animal  facility to commence the mouse skin wrinkles  studies.  The unusual
     strain of mice needed for these studies  (hairless mouse) has been imported
     into the animal facility and bred up to sufficient  numbers to commence the
     studies. It is anticipated that the lighting system should be in place in a
     few weeks and that the wrinkling studies will commence immediately it is in
     place.

12 MONTHS-

     Complete  wrinkle  model  studies


<PAGE>